February, 2025

article thumbnail

The Future of Training: How Virtual Reality Can Protect Clinicians from Healthcare-associated Infections

MedCity News

VR allows learners to actually see the virtual germs responsible for causing infections and spreading disease, which could otherwise only be seen under a microscope. The technology also heightens users’ senses, drawing their attention to things they would be unable to see in traditional learning environments. The post The Future of Training: How Virtual Reality Can Protect Clinicians from Healthcare-associated Infections appeared first on MedCity News.

Training 120
article thumbnail

International Day of Women and Girls in Science: Support and Empowerment

PharmaTech

Pharmaceutical Technology sat down with Michelle Bridenbaker, COO of Unbiased Science, ahead of International Day of Women and Girls in Science to talk about the role of women in the pharmaceutical industry.

article thumbnail

Bain Capital buys Mitsubishi Tanabe Pharma for $3.3bn

Pharmaceutical Technology

Bain Capital said its decision to buy Mitsubishi Tanabe is due to the strong growth potential of Japans healthcare industry.

Pharma 104
article thumbnail

FDA clears new antibiotic for superbug infections

pharmaphorum

AbbVie has won FDA approval for Emblaveo, a new antibiotic to treat pathogens that pose serious public health threats.

FDA 96
article thumbnail

AI in Marketing & Sales: Today’s Tools, Tomorrow’s Potential

Speaker: Kevin Burke

AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.

article thumbnail

Capgemini unveils AI breakthrough to boost bioeconomy

PharmaTimes

New methodology may boost innovation in protein engineering

article thumbnail

MHRA approves SARCLISA for newly diagnosed multiple myeloma

European Pharmaceutical Review

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for SARCLISA (isatuximab), making it the first and only anti-CD38 quadruplet therapy available for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). This decision provides a new first-line treatment option for thousands of patients in the UK facing this blood cancer.

More Trending

article thumbnail

Drugmakers prep for bird flu outbreak, despite continued low risk

PharmaVoice

While the virus hasn’t made a sustained leap into humans, vaccines and treatments are coming through the pipes if it does.

86
article thumbnail

Sanofi’s Sarclisa combo approved in China for multiple myeloma

Pharmaceutical Technology

Sanofi has received Chinas NMPA approval for the use of Sarclisa, combined with a standard-of-care regimen, for treating adults with NDMM.

104
104
article thumbnail

Share in cystic fibrosis firm Sionna rise sharply after IPO

pharmaphorum

Sionna has closed its IPO, raising $191m for cystic fibrosis candidates that it thinks could be more effective than rivals from Vertex.

89
article thumbnail

Aplagon secures EUR 7 million for APAC phase 2a trials

PharmaTimes

Funding led by new investors FSG and EIC Fund

87
article thumbnail

5 Ways You Can Win Faster with Gen AI in Sales

Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.

article thumbnail

Moderna reports record for UK clinical trials in 2023/24

European Pharmaceutical Review

Two years after signing its strategic partnership with the UK government, Moderna, Inc. has made substantial R&D investment and progress in the UK, the company has declared. The Moderna Innovation and Technology Centre (MITC) began construction in April 2023 as the companys state-of-the-art R&D and manufacturing facility. [Moderna] was the biggest industry sponsor of clinical trials in the UK in 2023/24″ The site is anticipated to be fully operational later in 2025, ready to delive

article thumbnail

Bain Capital Broadens Its Biotech Reach With $3.3B Deal for Mitsubishi Tanabe Pharma

MedCity News

Bain Capitals buyout of Mitsubishi Tanabe Pharma brings a company with a drug portfolio and pipeline in areas such as immunology, central nervous system disorders, and metabolic disease. This business is the pharmaceuticals division of Japanese conglomerate Mitsubishi Chemical Group. The post Bain Capital Broadens Its Biotech Reach With $3.3B Deal for Mitsubishi Tanabe Pharma appeared first on MedCity News.

Pharma 103
article thumbnail

Industry Outlook 2025: The Rising Prominence of AI in Pharma

PharmaTech

In this interview, Pharmaceutical Technology discusses the trend of AI in pharma and how it may play out in 2025 and beyond with Ben Sidders from Biorelate.

Pharma 65
article thumbnail

Sanofi increases ownership stake partaking in pharma buyback trend

Pharmaceutical Technology

Sanofi has agreed to purchase its own shares worth 2bn ($2.08bn), part of a $5.1bn share buyback initiative in 2025.

Pharma 98
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

GH Research leaps on psychedelic data in depression

pharmaphorum

After setbacks with psychedelics, phase 2b data with GH Research's GH001 for treatment-resistant depression could lift confidence in the category

94
article thumbnail

CHMP recommends SC Rybrevant for EGFR-mutated NSCLC patients

PharmaTimes

Positive opinion issued for marketing authorisation extension

article thumbnail

Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments

PharmaVoice

Fractyl Health is entering pivotal studies for a procedure that aims to be an ‘off ramp’ to GLP-1s and exploring how a one-time, ‘smart GLP-1’ gene therapy can Treat type 2 diabetes.

59
article thumbnail

Oral Metabolic Drug Acquired by Novo Nordisk Continues to Show Concerning Neuro Side Effects

MedCity News

Novo Nordisks monlunabant showed signs of neuropsychiatric side effects in a mid-stage diabetic kidney disease study, despite a drug design intended to favor hitting its target receptor in peripheral tissues rather than the brain. Neuro effects were also reported last year in a Phase 2 test of this pill in obesity. The post Oral Metabolic Drug Acquired by Novo Nordisk Continues to Show Concerning Neuro Side Effects appeared first on MedCity News.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Steps to Process Development Optimization

PharmaTech

The optimization of processes for the development and manufacture of biopharmaceuticals is pivotal for producing quality products.

article thumbnail

Thermo Fisher continues viral vector withdrawal; lays off 300 employees

Pharmaceutical Technology

The cuts at two Massachusetts plants follow further site closures and layoffs across the company over the past few years.

100
100
article thumbnail

Novo rises on Wegovy sales leap, but warns of a slowdown

pharmaphorum

Novo Nordisk is expecting greater competition and pricing pressure in the obesity and diabetes sectors this year.

article thumbnail

Novartis secures MHRA authorisation for ribociclib

PharmaTimes

Breast cancer therapy offers hope for patients at risk of recurrence

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Are orexins the next golden child of neuroscience?

PharmaVoice

An emerging class of orexin-based drugs are on the cusp of disrupting care for sleep disorders — and potentially much more.

59
article thumbnail

AI: A Good Tool to Combat Bad Actors in Healthcare

MedCity News

AI can be a highly effective tool for plans aiming to reduce fraud, waste and abuse, but only if it is combined with investigative intelligence. The post AI: A Good Tool to Combat Bad Actors in Healthcare appeared first on MedCity News.

article thumbnail

Alvogen Recalls Fentanyl Transdermal System

PharmaTech

The company is recalling one lot of Fentanyl Transdermal System 25 mcg/h transdermal patches because of possible multi-stacking of patches.

65
article thumbnail

Fourth person receives eGenesis’ gene-edited pig kidney transplant

Pharmaceutical Technology

Tim Andrews underwent the procedure with the pig kidney as part of a three-person compassionate use study.

90
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

BMS extends its cost-cutting drive by another $2bn

pharmaphorum

BMS is extending its bid to cut costs by $1.5bn before the end of this year, backed by 2,200 job cuts, adding a target of another $2bn by end-2027.

92
article thumbnail

Grifols collaborates with startup FcR Therapeutics to develop autoimmune therapies

PharmaTimes

Partnership aims to create recombinant nanobodies to treat immune disorders

71
article thumbnail

Pharma Pulse 2/10/25: AI Drug Discovery Impact on the Pharma Value Chain, Dementia Is Common and Somewhat Treatable & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 59
article thumbnail

Denali’s Data in Rare Enzyme Deficiency Keep It on Pace to Seek Speedy FDA Approval

MedCity News

Currently available therapies for Hunter syndrome dont cross the blood-brain barrier to address cognitive symptoms of the inherited enzyme deficiency. Denali Therapeutics’ technology gets its drug across the protective membrane, and the biotech plans to seek accelerated FDA approval in this rare disease. The post Denalis Data in Rare Enzyme Deficiency Keep It on Pace to Seek Speedy FDA Approval appeared first on MedCity News.

FDA 101
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.